WO2007020432A2 - High strength devices and composites - Google Patents

High strength devices and composites Download PDF

Info

Publication number
WO2007020432A2
WO2007020432A2 PCT/GB2006/003049 GB2006003049W WO2007020432A2 WO 2007020432 A2 WO2007020432 A2 WO 2007020432A2 GB 2006003049 W GB2006003049 W GB 2006003049W WO 2007020432 A2 WO2007020432 A2 WO 2007020432A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
polymer
oriented device
anhydride
oriented
Prior art date
Application number
PCT/GB2006/003049
Other languages
French (fr)
Other versions
WO2007020432A3 (en
Inventor
Malcolm Brown
Michael Andrew Hall
John Rose
Alan Bull
David F. Farrar
Original Assignee
Smith & Nephew, Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516943A external-priority patent/GB0516943D0/en
Priority claimed from GB0523318A external-priority patent/GB0523318D0/en
Application filed by Smith & Nephew, Plc filed Critical Smith & Nephew, Plc
Priority to JP2008526546A priority Critical patent/JP2009504929A/en
Priority to CA002619571A priority patent/CA2619571A1/en
Priority to EP06765297A priority patent/EP1922091A2/en
Priority to AU2006281248A priority patent/AU2006281248A1/en
Priority to US12/064,156 priority patent/US20080305144A1/en
Publication of WO2007020432A2 publication Critical patent/WO2007020432A2/en
Publication of WO2007020432A3 publication Critical patent/WO2007020432A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/502Plasticizers

Definitions

  • This invention relates to biodegradable polymeric devices and composites, particularly to bioresorbable devices and composites and to artifacts made therefrom and their uses.
  • High strength trauma fixation devices plates, screws, pins etc
  • metal typically titanium and stainless steel
  • metal devices have several well known disadvantages.
  • amorphous or semi-crystalline bioresorbable polymers such as poly (glycolic acid) (PGA) and poly (lactic acid) (PLA) are typically used to produce low load bearing devices- such as suture anchors, screws or tacs.
  • PGA poly (glycolic acid)
  • PLA poly (lactic acid)
  • One of the main criteria for using resorbable materials is that they carry out a mechanical function, degrade within a reasonable timeframe (for example, less than 3 yrs), and are ideally replaced by bone when used in bone sites.
  • these materials are not used in high load bearing applications because they are not strong or stiff enough to resist deformation under high load.
  • Drawn P(L)LA fibres and monoliths are also known.
  • drawn materials such as fibres and rods in which the polymer is oriented in the direction of drawing
  • the directional strength is dramatically increased.
  • Products from these combined approaches include fibre reinforced composites, using drawn fibre and a polymer matrix, and self-reinforced materials, using extruded billets which are die drawn into self reinforced rods.
  • WO 01/46501 discloses preparing a melt blend of polyester and multicarboxyiic acid having improved processability in an extruder and also having improved crystallization and absorption properties, envisaged for use in manufacturing nappies.
  • high strength fibres can be produced by incorporating plasticisers in the polymer blend, such as lauric acid, a fatty acid known from WO 03/004071 , to plasticise and accelerate the degradation of P(L)LA, and drawing the fibres to orient the polymer.
  • plasticisers such as lauric acid, a fatty acid known from WO 03/004071
  • the mechanical properties of drawn fibre were not compromised by the incorporation of plasticiser.
  • incorporating these plasticisers increased the degree of draw of the fibres during conventional hot drawing but decreased the drawing temperature.
  • an oriented implantable, biodegradable device formed from a homogeneous polymer blend comprising a poly lactic acid (PLA) in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer draw and which is a degradation accelerant wherein polymer comprised within the polymer blend is in uniaxial, biaxial or triaxial orientation.
  • PVA poly lactic acid
  • the additive is biocompatible.
  • the additive may be suitable for any application and is advantageously suitable for use in medical applications.
  • the additive is a carboxylic acid or precursor thereof.
  • an acid precursor is a carboxyl containing compound and is selected from an acid anhydride, ester or other acid precursor.
  • the acid may be a mono or poly saturated or unsaturated acid, more particularly a mono or diacid.
  • the acid is a monoacid or precursor thereof.
  • the acid is suitably a C 4- 24 carboxylic acid or precursor.
  • suitable additives include the group consisting of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4- hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2- butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3- methylvaleric acid, 4-methylvaleric acid, 2-e
  • the oriented PLA polymer of the invention is characterised by improved degradation properties, equivalent mechanical properties and enhanced draw with respect to the original drawn PLA polymer.
  • Reference herein to an oriented device is to a device comprised of oriented polymer as known in the art, also known as aligned polymer, wherein the polymer is in uniaxial, biaxial or triaxial alignment.
  • polymers comprise discrete polymer chains which may be aligned or oriented to render the polymer in uniaxial, biaxial or triaxial alignment. Alignment or orientation is suitably conferred by further processing in suitable manner and as hereinafter defined.
  • the oriented device of the invention is therefore distinct from polymer which has not been further processed to confer orientation, and in which polymer chains are typically in random alignment. Orientation may be determined by techniques as known in the art for example scanning electron microscopy (SEM), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), X-ray, optical microscopy and the like.
  • a advantageous additive for use in the invention is lauric acid or benzoic acid. This may be employed as the acid per se or, if desired, as a precursor, for example as the anhydride.
  • the additive will not only control the rate of degradation but will delay the onset of the degradation process relative to the acid. This delay may be achieved, aptly by the use of precursors which are convertible to the acidic form of the additive. Suitable precursors are acid anhydrides which will, in an in vivo environment, hydrolyse to the corresponding acid.
  • Example anhydrides include lauric anhydride and benzoic anhydride.
  • the polymer blend will contain not more than 5%, and more aptly not more than 2%, by weight of the additive and typically the blend will contain not more than 1% by weight of the additive.
  • Example blends will contain not more than 2%, ideally not more than 1 %, by weight of the blend of lauric acid or a precursor thereof.
  • the amount of the additive chosen will also depend upon the nature of the additive and the rate of degradation desired.
  • the polymeric component of the polymer blends useful for the invention essentially comprise a biodegradable PLA, including homopolymers, (block) copolymers, blends, individual or mixed isomers and the like, which may be bioresorbable, bioerodible or display any other form of degradation, for example instability to water, heat or acid, polymer.
  • the PLA may be suitable for any application and is advantageously suitable for medical applications, for example is suitable for implantation into the human or animal body.
  • An oriented device of the invention may be single phase (amorphous) or biphasic (semi crystalline and amorphous).
  • Suitably blends are of miscible polymers.
  • Suitable biodegradable PLA's are selected from poly(lactic acid), isomers thereof including P(L)LA, P(D)LA, P(D 1 L)LA, blends and copolymers thereof.
  • a co-polymer for use in the blend of the invention may comprise more than one PLA as hereinbefore defined or may comprise other known biodegradable polymeric components copolymerised therewith, such as polyesters, including poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acids, copolymers of lactic and glycolic acid with poly(ethylene glycol), poly(e-caprolactone), poly(3-hydroxybutyrate), poly(p-dioxanone), poly(propylene fumarate), poly(trimethylene carbonate) and the like.
  • polyesters including poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acids, copolymers of lactic and glycolic acid with poly(ethylene glycol), poly(e-caprolactone), poly(3-hydroxybutyrate), poly(p-dioxanone), poly(propylene fumarate), poly(trimethylene carbonate) and the like.
  • the copolymer is a copolymer with another poly(lactic acid) or with poly glycolic acid, for example a copolymer of poly(lactic acids) such as P(L)LA/P(D)LA copolymer, or a copolymer of poly(lactic acid) and glycolic acid (known as PLA/PGA co-polymer).
  • the blend may, in addition to the additive, consist of a blend of PLAs or copolymers as hereinbefore defined with other biodegradable polymeric components, for example, polyesters, for .
  • a blend of polylactic acid or PLA/PGA co-polymer either alone or in admixture with each other.
  • Molecular weight of the polymeric component may be selected according to the particular polymer to be used and the intended use of the device of the invention, and therefore the required strength and modulus.
  • the polymeric component has number average molecular weight (Mn) in oriented form in the range in excess of 30,000 daltons or alternatively in the range 50,000 to 500,000 daltons.
  • Mn number average molecular weight
  • Molecular weight of the oriented device for higher strength applications, for example oriented fibres may be in the range 100,000 to 400,000 daltons.
  • Molecular weight may be determined in known manner, for example by gel permeation chromatography (GPC), viscometry or the like.
  • polymeric component is selected with an intrinsic viscosity (IV), in the range 1 to 10, and more particularly 2 to 5.
  • IV intrinsic viscosity
  • the oriented device may also contain fillers such as osteoconductive materials and the like and/or biological actives such as hydroxyapatite.
  • the oriented device of the invention may be provided in the form of fibres, drawn monoliths such as rods and the like, spun or moulded devices or may be used to produce high strength composites reinforced by component fibres, drawn monoliths, spun or moulded polymer and the like.
  • Fibres may be continuous or chopped.
  • Reference herein to fibres includes fibres, yarns, strands, whiskers, filaments, ribbons, tapes and the like.
  • Drawn devices may be singly or multiply drawn.
  • the oriented device of the invention is characterised by properties of high strength.
  • the device has a tensile strength in excess of about 150 MPa up to about 2000 MPa depending on the polymer components and the form thereof.
  • Tensile strength may be in the range from about 800 to about 2000 MPa, for example about 800 to about 1000 or about 1000 to about 2000 MPa, for fibre form devices, or in the range about 150 to about 800 MPa for drawn monoliths, spun or moulded polymer. This compares with a tensile strength of undrawn PLA fibres of the order of 70 MPa.
  • the polymer matrix is a bioresorbable polymer, and may be selected from any bioresorbable polymer, for example a polyester, such as PLA or the like and its isomers and copolymers and blends thereof as hereinbefore defined.
  • the polymer matrix is selected from PLA, P(L)LA, P(D)LA, P(D 1 L)LA, PGA, polycaprolactone (PCL) and the like and (block) copolymers and blends thereof.
  • a matrix polymer may be formed from a homogeneous polymer blend comprising the polymer(s) in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer and which is a degradation accelerant as hereinbefore defined.
  • a composite of the invention may also contain fillers such as osteoconductive materials and/or biological actives such as hydroxyapatite in the matrix and/or the oriented device.
  • the composite comprises oriented device present in a known manner, for example provided as random or aligned fibres, a fabric in woven or unwoven or braided form or as a scrim, mesh, preform or prepreg.
  • Fabrics may be mats, felts, veils, braided, knitted, punched, non-crimp, polar-, spiral- or uni-weaves, tailored fibre placement fabrics and the like.
  • Composite may comprise continuous or chopped oriented fibres of the invention.
  • the oriented device may be present in any desired amount, for example in an amount of from about 1 wt% to about 70wt% of the composite.
  • a composite of the invention is biodegradable and may comprise any implantable device where temporary residence only is required.
  • implantable devices include suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods and the like.
  • the composite of the invention is characterised by properties of high strength.
  • the composite of the invention has tensile strength in excess of 150 MPa up to 800 MPa depending on the constituent polymer components and matrix polymer and the composite form.
  • Tensile strength is, for example, in the range about
  • a process for the preparation of an oriented device as hereinbefore defined comprising preparing a polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer draw and which is a degradation accelerant as hereinbefore defined, and processing to orient polymer whereby polymer is in uniaxial, biaxial or triaxial orientation.
  • Polymer component is commercially available or may be prepared by processes as known in the art.
  • the polymer blends used for the present invention may be produced by known processes such as solution blending wherein the additive is blended directly into a solution of a polymeric component comprising for example, PLA in chloroform, by melt blending in melt phase, or by dry blending the solid polymer and additive materials and then solution blending the solid mixture with solvent such as chloroform. The solution blend is then dried to form a solid blend or is cast onto a surface and dried.
  • the polymer blend is cast, compression moulded or extruded into a form suitable for shaping and orienting, for example moulding or extruding as monolith such as billets or rods, or fibre or film, and oriented by any known process that induces orientation into a polymer, selected from uniaxial, biaxial or triaxial orientation as hereinbefore defined.
  • Casting or compression-moulding may be conducted by rendering the solid blend in melt phase for shaping into a desired form for orienting.
  • Extrusion may be of powder or pellets as a dry blend from a hopper with extrusion via a suitable die to the desired shape.
  • orienting is by aligning melt phase polymer blend and cooling, more particularly by drawing, spinning or moulding melt phase polymer blend to orient polymer chains in the direction of draw or spin, or axis or direction of moulding, and cooling, such as drawing, for example fibre drawing produces increased strength and modulus fibre, or (hydrostatic) die drawing produces an increased strength or modulus rod or the like, spinning for example gel spinning or solution spinning produces increased strength or modulus fibre, moulding for example Shear Controlled Orientation in Injection Moulding (SCORIM) produces increased strength or modulus fibre, rod or shaped polymer, and the like.
  • high strength oriented device may be produced by processing to orient the polymer using any of the following processes: -
  • polyester fibre e.g. P(L)LA fibre
  • hydrostatic die drawing or die drawing to produce a high strength-high modulus fast degrading polyester rod (e.g. P(L)LA rod);
  • solution processing such as gel spinning or solution spinning (to produce fibre at ambient temperature from solution, with subsequent solvent removal;
  • Drawing, spinning and moulding processes are known in the art. Drawing is undertaken, for example, by feeding the moulded film or extrudate at elevated temperature through a die and drawing the polymer, whereby the polymer chains orient in the direction of drawing, and cooling. Drawing may be conducted in two stages or passes.
  • an oriented device of the invention may be used to prepare a polymer composite as hereinbefore defined.
  • Composites according to the invention may be prepared by providing the oriented device in desired form and combining with matrix polymer as hereinbefore defined.
  • Matrix polymer is suitably combined in solid, solution or melt form with the oriented device in accordance with the invention and hardened for example by moulding, compression moulding or drying.
  • Matrix may be combined by blending, impregnation, infusion, injection or the like as known in the art.
  • an additive- containing blend as hereinbefore defined may be utilized to prepare both oriented device and matrix component of a composite material which is then fabricated into a high strength biodegradable composite device as hereinbefore or hereinbelow defined.
  • an oriented device or a composite thereof as hereinbefore defined as an implantable biodegradable device such as a high strength trauma fixation device suitable for implantation into the human or animal body, for example plates, screws, pins, rods, anchors or scaffolds, in particular suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods and the like.
  • Figure 1 illustrates the degradation profile of drawn P(L)LA and drawn P(L)LA/nica acid (LA) fibres with time.
  • Figure 2 illustrates the molecular weight (Mn) change of drawn P(L)LA and drawn P(L)LA/LA fibres with time.
  • the viscous solutions were cast by poured them out into release paper trays, in order to produce thick sheets of polymer suitable for subsequent granulation.
  • the sheets were left to dry for 2 days in the fume cupboard before undergoing the subsequent drying procedure:
  • the sheets were then granulated with the Cumberland mechanical grinder (fitted with 3mm sieve), after having been dipped into liquid nitrogen to render them more brittle. All the granules were further dried under vacuum at 100 0 C for 4 hours, and left under vacuum at room temperature for 3 days.
  • the extruder was fitted with a general-purpose 12mm screw with a 25:1 L/D ratio.
  • the extruder was fitted with a 2mm (diameter) die (coated) with a L/D ratio of 6:1.
  • the fibre was produced using a flat temperature profile of 240° C for all zones.
  • a nominal 0.5mm diameter fibre was produced (using maximum screw speed of 50rpm) and hauled off at a rate of 16 meters per minute.
  • the diameter of the fibre was monitored during the run using a Mitutoyo laser micrometer.
  • the extruded fibre was sealed in a foil pouch containing a desiccant sachet and then stored in a freezer at - 20° C prior to further processing.
  • Fibre drawing was carried out using a customised drawing rig.
  • the rig consists of two sets of godets and heated plate (hot shoe).
  • the godets were preset to rotate at different speeds.
  • the fibre was feed from a spindle, through the 1 st set of godets, drawn over the hot shoe and around the 2 nd set of godets.
  • the drawn fibre was finally collected on a Leesona fibre winder.
  • the fibres were drawn under various temperatures and speeds to produced fibres with different properties as shown in Table 1.
  • Fibre was drawn using a batch zone drawing process.
  • a cylindrical brass zone (outer diameter 25mm, inner diameter 5mm, 63mm length) was attached to a moving plate.
  • the temperature was controlled using a temperature probe connected to the zone and temperature controls.
  • a clamp was fixed at a given height above the zone, 1 metre length of fibre was clamped at 1 end, threaded through the zone (using a brass rod), and the load was attached to the free end of the fibre. Fibre was then drawn under various speed, load and zone temperatures.
  • Carrier gas Helium
  • Table 3 shows the amount of lauric acid contained in each P(L)UVLA fibre.
  • the fibres were subjected to in vitro degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 0 C.
  • PBS phosphate buffer solution

Abstract

An oriented implantable, biodegradable device is disclosed. The oriented implantable, biodegradable device is formed from a homogeneous polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant. The polymer comprised within the blend may be a uniaxial, biaxial or triaxial orientation. Also disclosed is a composite thereof, processes for the preparation thereof, and The implantable biodegradable device may be used as a high strength trauma fixation device suitable for implantation into the human or animal body. As examples, the high strength trauma fixation device may take the form of plates, screws, pins, rods, anchors or scaffolds.

Description

High Strength Devices and Composites
This application claims the benefit of U.K. Provisional
Application No. 0516943.8 filed August 18, 2005 and U.K.
Provisional Application No. 0523318.4, filed November 16, 2005 both entitled "High strength fibres and composites" and the entire contents of which are hereby incorporated by reference.
Technical Field of the invention
This invention relates to biodegradable polymeric devices and composites, particularly to bioresorbable devices and composites and to artifacts made therefrom and their uses.
Background of the invention
High strength trauma fixation devices (plates, screws, pins etc) are presently made of metal, typically titanium and stainless steel, however metal devices have several well known disadvantages.
Currently amorphous or semi-crystalline bioresorbable polymers such as poly (glycolic acid) (PGA) and poly (lactic acid) (PLA) are typically used to produce low load bearing devices- such as suture anchors, screws or tacs. One of the main criteria for using resorbable materials is that they carry out a mechanical function, degrade within a reasonable timeframe (for example, less than 3 yrs), and are ideally replaced by bone when used in bone sites. However, these materials are not used in high load bearing applications because they are not strong or stiff enough to resist deformation under high load.
To overcome these deficiencies, a composite approach has been applied to generate stiffer and/or stronger bioresorbable materials. Poly (L) lactic acid (P(L)LA) fibre - composites are known.
Drawn P(L)LA fibres and monoliths are also known. By incorporating drawn materials, such as fibres and rods in which the polymer is oriented in the direction of drawing, the directional strength is dramatically increased. Products from these combined approaches include fibre reinforced composites, using drawn fibre and a polymer matrix, and self-reinforced materials, using extruded billets which are die drawn into self reinforced rods.
However, drawn P(L)LA fibres are reported to have longer degradation times of up to 40 years
To address this deficiency, acid accelerants have been incorporated into the P(L)LA polymer (WO 03/004071 ) to produce faster degrading P(L)LA blocks. However it is known that adding these accelerants to the polymer plasticises the base polymer.
Whilst the incorporation of these acid accelerants does not seriously compromise the mechanical properties of moulded P(L)LA block, the incorporation of a plasticiser into high strength fibre is expected to reduce both the strength and modulus of the drawn fibres.
WO 01/46501 discloses preparing a melt blend of polyester and multicarboxyiic acid having improved processability in an extruder and also having improved crystallization and absorption properties, envisaged for use in manufacturing nappies.
In US Patent Specification No. 5,527,337 there is disclosed a biodegradable stent formed from woven lactide polymer fibres wherein, inter alia, an excipient such as citric acid or fumaric acid can be incorporated with lactide polymers during the polymer processing to improve biodegradability. However, the fibres of WO 01/46501 and US 5,527,337 are not required to have a high load- bearing performance, but rather are intended to display elastic or absorptive properties and, therefore, would not be suitable for the presently envisaged applications. Thus it would be desirable to produce a PLLA high strength fibre and composite with a reduced degradation time without compromising the mechanical properties of the composite.
We have now surprisingly found that high strength fibres can be produced by incorporating plasticisers in the polymer blend, such as lauric acid, a fatty acid known from WO 03/004071 , to plasticise and accelerate the degradation of P(L)LA, and drawing the fibres to orient the polymer. Surprisingly the mechanical properties of drawn fibre were not compromised by the incorporation of plasticiser. We have also found that incorporating these plasticisers increased the degree of draw of the fibres during conventional hot drawing but decreased the drawing temperature.
Summary of the invention
Thus, in accordance with the broadest aspect of the present invention there is provided an oriented implantable, biodegradable device formed from a homogeneous polymer blend comprising a poly lactic acid (PLA) in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer draw and which is a degradation accelerant wherein polymer comprised within the polymer blend is in uniaxial, biaxial or triaxial orientation.
Suitably, the additive is biocompatible. The additive may be suitable for any application and is advantageously suitable for use in medical applications. In an embodiment of the invention the additive is a carboxylic acid or precursor thereof. As an example, an acid precursor is a carboxyl containing compound and is selected from an acid anhydride, ester or other acid precursor. The acid may be a mono or poly saturated or unsaturated acid, more particularly a mono or diacid. In an embodiment of the invention the acid is a monoacid or precursor thereof. The acid is suitably a C4-24 carboxylic acid or precursor. Examples of suitable additives include the group consisting of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4- hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2- butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3- methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans- beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4- pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen-1-yl succinic anhydride and phthalic anhydride and mixtures thereof.
In a particular advantage the oriented PLA polymer of the invention is characterised by improved degradation properties, equivalent mechanical properties and enhanced draw with respect to the original drawn PLA polymer.
Reference herein to an oriented device is to a device comprised of oriented polymer as known in the art, also known as aligned polymer, wherein the polymer is in uniaxial, biaxial or triaxial alignment. As known in the art, polymers comprise discrete polymer chains which may be aligned or oriented to render the polymer in uniaxial, biaxial or triaxial alignment. Alignment or orientation is suitably conferred by further processing in suitable manner and as hereinafter defined. The oriented device of the invention is therefore distinct from polymer which has not been further processed to confer orientation, and in which polymer chains are typically in random alignment. Orientation may be determined by techniques as known in the art for example scanning electron microscopy (SEM), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), X-ray, optical microscopy and the like.
We have found that a advantageous additive for use in the invention is lauric acid or benzoic acid. This may be employed as the acid per se or, if desired, as a precursor, for example as the anhydride.
In an embodiment of the present invention, the additive will not only control the rate of degradation but will delay the onset of the degradation process relative to the acid. This delay may be achieved, aptly by the use of precursors which are convertible to the acidic form of the additive. Suitable precursors are acid anhydrides which will, in an in vivo environment, hydrolyse to the corresponding acid. Example anhydrides include lauric anhydride and benzoic anhydride.
Aptly the polymer blend will contain not more than 5%, and more aptly not more than 2%, by weight of the additive and typically the blend will contain not more than 1% by weight of the additive. Example blends will contain not more than 2%, ideally not more than 1 %, by weight of the blend of lauric acid or a precursor thereof.
The amount of the additive chosen will also depend upon the nature of the additive and the rate of degradation desired.
The polymeric component of the polymer blends useful for the invention essentially comprise a biodegradable PLA, including homopolymers, (block) copolymers, blends, individual or mixed isomers and the like, which may be bioresorbable, bioerodible or display any other form of degradation, for example instability to water, heat or acid, polymer. The PLA may be suitable for any application and is advantageously suitable for medical applications, for example is suitable for implantation into the human or animal body. An oriented device of the invention may be single phase (amorphous) or biphasic (semi crystalline and amorphous). Suitably blends are of miscible polymers.
Suitable biodegradable PLA's are selected from poly(lactic acid), isomers thereof including P(L)LA, P(D)LA, P(D1L)LA, blends and copolymers thereof.
A co-polymer for use in the blend of the invention may comprise more than one PLA as hereinbefore defined or may comprise other known biodegradable polymeric components copolymerised therewith, such as polyesters, including poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acids, copolymers of lactic and glycolic acid with poly(ethylene glycol), poly(e-caprolactone), poly(3-hydroxybutyrate), poly(p-dioxanone), poly(propylene fumarate), poly(trimethylene carbonate) and the like. In embodiments of the invention the copolymer is a copolymer with another poly(lactic acid) or with poly glycolic acid, for example a copolymer of poly(lactic acids) such as P(L)LA/P(D)LA copolymer, or a copolymer of poly(lactic acid) and glycolic acid (known as PLA/PGA co-polymer).
Additionally the blend may, in addition to the additive, consist of a blend of PLAs or copolymers as hereinbefore defined with other biodegradable polymeric components, for example, polyesters, for . example a blend of polylactic acid or PLA/PGA co-polymer either alone or in admixture with each other.
Molecular weight of the polymeric component may be selected according to the particular polymer to be used and the intended use of the device of the invention, and therefore the required strength and modulus. In embodiments of the invention the polymeric component has number average molecular weight (Mn) in oriented form in the range in excess of 30,000 daltons or alternatively in the range 50,000 to 500,000 daltons. Molecular weight of the oriented device for higher strength applications, for example oriented fibres, may be in the range 100,000 to 400,000 daltons. Molecular weight may be determined in known manner, for example by gel permeation chromatography (GPC), viscometry or the like.
Suitably polymeric component is selected with an intrinsic viscosity (IV), in the range 1 to 10, and more particularly 2 to 5.
The oriented device may also contain fillers such as osteoconductive materials and the like and/or biological actives such as hydroxyapatite.
The oriented device of the invention may be provided in the form of fibres, drawn monoliths such as rods and the like, spun or moulded devices or may be used to produce high strength composites reinforced by component fibres, drawn monoliths, spun or moulded polymer and the like. Fibres may be continuous or chopped. Reference herein to fibres includes fibres, yarns, strands, whiskers, filaments, ribbons, tapes and the like. Drawn devices may be singly or multiply drawn.
The oriented device of the invention is characterised by properties of high strength. In embodiments of the invention the device has a tensile strength in excess of about 150 MPa up to about 2000 MPa depending on the polymer components and the form thereof. Tensile strength may be in the range from about 800 to about 2000 MPa, for example about 800 to about 1000 or about 1000 to about 2000 MPa, for fibre form devices, or in the range about 150 to about 800 MPa for drawn monoliths, spun or moulded polymer. This compares with a tensile strength of undrawn PLA fibres of the order of 70 MPa.
In a further aspect of the invention there is provided a composite comprising an oriented device as hereinbefore defined In embodiments of the invention the polymer matrix is a bioresorbable polymer, and may be selected from any bioresorbable polymer, for example a polyester, such as PLA or the like and its isomers and copolymers and blends thereof as hereinbefore defined.
In an embodiment of the invention the polymer matrix is selected from PLA, P(L)LA, P(D)LA, P(D1L)LA, PGA, polycaprolactone (PCL) and the like and (block) copolymers and blends thereof.
A matrix polymer may be formed from a homogeneous polymer blend comprising the polymer(s) in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer and which is a degradation accelerant as hereinbefore defined.
A composite of the invention may also contain fillers such as osteoconductive materials and/or biological actives such as hydroxyapatite in the matrix and/or the oriented device.
In an embodiment of the invention the composite comprises oriented device present in a known manner, for example provided as random or aligned fibres, a fabric in woven or unwoven or braided form or as a scrim, mesh, preform or prepreg. Fabrics may be mats, felts, veils, braided, knitted, punched, non-crimp, polar-, spiral- or uni-weaves, tailored fibre placement fabrics and the like. Composite may comprise continuous or chopped oriented fibres of the invention.
The oriented device may be present in any desired amount, for example in an amount of from about 1 wt% to about 70wt% of the composite.
A composite of the invention is biodegradable and may comprise any implantable device where temporary residence only is required. Examples of such devices include suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods and the like.
The composite of the invention is characterised by properties of high strength. For example, the composite of the invention has tensile strength in excess of 150 MPa up to 800 MPa depending on the constituent polymer components and matrix polymer and the composite form. Tensile strength is, for example, in the range about
250 to about 550 MPa, for example about 350 to about 500 MPa comprising fibre form devices, drawn monoliths, spun or moulded devices.
In a further aspect of the invention there is provided a process for the preparation of an oriented device as hereinbefore defined comprising preparing a polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which plasticises polymer draw and which is a degradation accelerant as hereinbefore defined, and processing to orient polymer whereby polymer is in uniaxial, biaxial or triaxial orientation.
Polymer component is commercially available or may be prepared by processes as known in the art.
The polymer blends used for the present invention may be produced by known processes such as solution blending wherein the additive is blended directly into a solution of a polymeric component comprising for example, PLA in chloroform, by melt blending in melt phase, or by dry blending the solid polymer and additive materials and then solution blending the solid mixture with solvent such as chloroform. The solution blend is then dried to form a solid blend or is cast onto a surface and dried. In an embodiment of the invention the polymer blend is cast, compression moulded or extruded into a form suitable for shaping and orienting, for example moulding or extruding as monolith such as billets or rods, or fibre or film, and oriented by any known process that induces orientation into a polymer, selected from uniaxial, biaxial or triaxial orientation as hereinbefore defined.
Casting or compression-moulding may be conducted by rendering the solid blend in melt phase for shaping into a desired form for orienting. Extrusion may be of powder or pellets as a dry blend from a hopper with extrusion via a suitable die to the desired shape.
In an embodiment of the invention orienting is by aligning melt phase polymer blend and cooling, more particularly by drawing, spinning or moulding melt phase polymer blend to orient polymer chains in the direction of draw or spin, or axis or direction of moulding, and cooling, such as drawing, for example fibre drawing produces increased strength and modulus fibre, or (hydrostatic) die drawing produces an increased strength or modulus rod or the like, spinning for example gel spinning or solution spinning produces increased strength or modulus fibre, moulding for example Shear Controlled Orientation in Injection Moulding (SCORIM) produces increased strength or modulus fibre, rod or shaped polymer, and the like. Preferably high strength oriented device may be produced by processing to orient the polymer using any of the following processes: -
By fibre drawing to produce a high strength-high modulus fast degrading polyester fibre (e.g. P(L)LA fibre);
By hydrostatic die drawing or die drawing to produce a high strength-high modulus fast degrading polyester rod (e.g. P(L)LA rod); By solution processing such as gel spinning or solution spinning (to produce fibre at ambient temperature from solution, with subsequent solvent removal;
By SCORIM or the like to produce monoliths with orientation by shearing effect of pistons.
Drawing, spinning and moulding processes are known in the art. Drawing is undertaken, for example, by feeding the moulded film or extrudate at elevated temperature through a die and drawing the polymer, whereby the polymer chains orient in the direction of drawing, and cooling. Drawing may be conducted in two stages or passes.
In a further aspect of the invention, an oriented device of the invention may be used to prepare a polymer composite as hereinbefore defined. Composites according to the invention may be prepared by providing the oriented device in desired form and combining with matrix polymer as hereinbefore defined. Matrix polymer is suitably combined in solid, solution or melt form with the oriented device in accordance with the invention and hardened for example by moulding, compression moulding or drying. Matrix may be combined by blending, impregnation, infusion, injection or the like as known in the art. In an embodiment of the invention an additive- containing blend as hereinbefore defined may be utilized to prepare both oriented device and matrix component of a composite material which is then fabricated into a high strength biodegradable composite device as hereinbefore or hereinbelow defined.
In a further aspect of the invention there is provided the use of an oriented device or a composite thereof as hereinbefore defined as an implantable biodegradable device such as a high strength trauma fixation device suitable for implantation into the human or animal body, for example plates, screws, pins, rods, anchors or scaffolds, in particular suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods and the like.
Brief Description of the drawings
The present invention will be illustrated in non-limiting manner by reference to the following examples and accompanying figure and drawings wherein:
Figure 1 illustrates the degradation profile of drawn P(L)LA and drawn P(L)LA/ Laurie acid (LA) fibres with time.
Figure 2 illustrates the molecular weight (Mn) change of drawn P(L)LA and drawn P(L)LA/LA fibres with time.
Example 1 - P(ϋLA/lauric acid(LA) blend production
The following blends were produced by solution blending:-
(I) Polymer P(L)LA IV=3.82 (213.21 g) (Purac) + lauric acid (LA) (1.07 g)
(II) Polymer P(L)LA IV=4.51(213.21 g) (Purac) + lauric acid (LA) (1.07 g)
METHODS
The solids placed in each jar were thoroughly mixed by shaking the jars and split into 3 separate jars. 950 mL of CHCI3 was added to each of the 3 jars, and the jars placed on agitating rollers for around 10 hours to dissolve the polymer.
Once the polymer was dissolved, the viscous solutions were cast by poured them out into release paper trays, in order to produce thick sheets of polymer suitable for subsequent granulation. The sheets were left to dry for 2 days in the fume cupboard before undergoing the subsequent drying procedure:
600C under vacuum for 6.5h + room temperature under vacuum overnight;
800C under vacuum for 5h + room temperature under vacuum over weekend; or
1000C under vacuum for 4h
The sheets were then granulated with the Cumberland mechanical grinder (fitted with 3mm sieve), after having been dipped into liquid nitrogen to render them more brittle. All the granules were further dried under vacuum at 1000C for 4 hours, and left under vacuum at room temperature for 3 days.
Example 2 - Fibre production
The following methodology was used to produce both P(L)LA and P(L)LA/LA fibres
METHOD
The polymer (P(L)LA - IV= 3.8/ Purac) or polymer blend (P(L)LA-IV 3.8/Purac/ lauric acid) was extruded using a Rondol 12mm extruder. The extruder was fitted with a general-purpose 12mm screw with a 25:1 L/D ratio. The extruder was fitted with a 2mm (diameter) die (coated) with a L/D ratio of 6:1. The fibre was produced using a flat temperature profile of 240° C for all zones. A nominal 0.5mm diameter fibre was produced (using maximum screw speed of 50rpm) and hauled off at a rate of 16 meters per minute. The diameter of the fibre was monitored during the run using a Mitutoyo laser micrometer. The extruded fibre was sealed in a foil pouch containing a desiccant sachet and then stored in a freezer at - 20° C prior to further processing. Example 3 - Drawn Fibre
The following methodologies were used to draw both P(L)LA and P(L)LA/LA fibres
METHOD 1 : Hot shoe
Fibre drawing was carried out using a customised drawing rig. The rig consists of two sets of godets and heated plate (hot shoe). The godets were preset to rotate at different speeds. The fibre was feed from a spindle, through the 1st set of godets, drawn over the hot shoe and around the 2nd set of godets. The drawn fibre was finally collected on a Leesona fibre winder.
RESULTS
The fibres were drawn under various temperatures and speeds to produced fibres with different properties as shown in Table 1.
Table 1
(a) PLLA/LA
Figure imgf000015_0001
(b) PLLA
Figure imgf000016_0001
These drawn fibres were mechanically tested, using an lnstron 5566 with a crosshead speed of 10mm/min and a gauge length of 35mm. The fibre diameter was measured using callipers and micrometers. The total draw ratio (defined as the square of initial fibre diameter /square of final fibre diameter) is given with the strength and modulus data below. Incorporating the LA increased the degree of draw of the fibres during conventional hot drawing at decreased drawing temperature.
METHOD 2: Zone drawn
Fibre was drawn using a batch zone drawing process. A cylindrical brass zone (outer diameter 25mm, inner diameter 5mm, 63mm length) was attached to a moving plate. The temperature was controlled using a temperature probe connected to the zone and temperature controls. A clamp was fixed at a given height above the zone, 1 metre length of fibre was clamped at 1 end, threaded through the zone (using a brass rod), and the load was attached to the free end of the fibre. Fibre was then drawn under various speed, load and zone temperatures.
The samples were drawn using the following drawing conditions shown in Table 2. Table 2
Figure imgf000017_0001
Draw Speed *= 200mm/min, **= 50 mm/min
RESULTS
The results showed equivalent results for drawn fibres with and without LA additive.
Example 4 - Laurie acid determination
METHOD
Approx. 0.1 g of each PLA/LA sample was dissolved in approx. 10ml chloroform. Internal standard was added via glass pipette (0.9mg/ml Hexanoic acid in acetone). Samples were left overnight to dissolve. 20-3OmI of diethyl ether was added to precipitate the polymer. An aliquot of each solution was filtered through 0.45μm PTFE GDX Whatman syringe filters into injection vials. The analysis was carried out using Gas Chromatography under the following conditions: - GC System: 3
Column: Phenomenex ZB-FFAP (30m x 0.53mm x 1 μm)
Head pressure: 6 psi
Carrier gas: Helium
Split gas flow: 15 ml/min
Hydrogen gas flow: 45 ml/min
Nitrogen gas flow: 20 ml/min
Oven Program: Initial temp: 200 0C
Initial time: 2 min
Rate of ramp: 5 °C/min
Final temp: 240 0C
Total Run Time: 10 min
Injector temp: 250 0C
Injection volume: 1 μl
Detector temp: 25O 0C
Detection: FID
RESULTS
Table 3 shows the amount of lauric acid contained in each P(L)UVLA fibre.
Table 3
Figure imgf000018_0001
Example 5 - degradation - tensile strength
METHOD
The fibres were subjected to in vitro degradation by immersion in standard phosphate buffer solution (PBS), maintained at 370C.
During the ten week test period samples were analysed to determine the tensile strength of the fibres using a gauge length of 40mm and a test speed of 10mm/min.
RESULTS
The results are reported in Figure 1 which shows a higher tensile strength of P(L)LA/LA (0.4%) for the initial 3 weeks, thereafter declining below that of drawn P(L)LA fibres over 5 weeks. Drawn P(L)LA fibres show a steady tensile strength over the initial 10 weeks. The degradation rate of P(L)LA/LA (0.4%) could be delayed by using a precursor of LA, for example Laurie anhydride.
Samples were also analysed to determine molecular weight (Mn) of the polymer fibres during the ten week test period, the results are reported in Figure 2.
In view of the foregoing, it will be seen that the several advantages of the invention are achieved and attained.
The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated.
As various modifications could be made in the methods herein described and illustrated without departing from the scope of the invention, it is intended that all matter contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative rather than limiting. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims appended hereto and their equivalents.

Claims

Claims
1. An oriented implantable, biodegradable device formed from a homogeneous polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant , or a precursor thereof, wherein polymer comprised within the polymer blend is in uniaxial, biaxial or triaxial orientation.
2. An oriented device as claimed in claim 1 wherein the additive is a carboxylic acid or precursor thereof.
3. An oriented device as claimed in claim 2 wherein a precursor is a carboxyl containing compound.
4. An oriented device as claimed in claim 2 or 3 wherein a precursor is selected from an acid anhydride, ester or other acid precursor.
5. An oriented device as claimed in any of claims 2 to 4 wherein the acid is a mono or poly saturated or unsaturated acid such as a diacid, or precursor thereof.
6. An oriented device as claimed in any of claims 1 to 5 wherein an additive is selected from the group consisting of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4- isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4- hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2- butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3- methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans- beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4- pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen-1-yl succinic anhydride and phthalic anhydride, benzoic acid or benzoic anhydride and mixtures thereof.
7. An oriented device as claimed in any one of the previous claims wherein the additive is lauric acid or lauric anhydride.
8. An oriented device as claimed in any of claims 1 to 7, wherein the polymer blend contains not more than 2%, by weight of the additive.
9. An oriented device as claimed in any one of the preceding claims wherein the lactic acid polymer is selected from polylactic acid and isomers thereof including P(L)LA, P(D)LA, P(D1L)LA, blends and (block) copolymers thereof.
10. An oriented device as claimed in claim 9 wherein a lactic acid (block) copolymer is selected from a copolymer of a polylactic acid homopolymer as defined in Claim 9 with a polyester, including poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acids, copolymers of lactic and glycolic acid with poly(ethylene glycol), poly(e-caprolactone), poly(3-hydroxybutyrate), poly(p- dioxanone), poly(propylene fumarate) and poly(trimethylene carbonate).
11. An oriented device as claimed in any one of claims 1 to 10 wherein the polymeric component has molecular weight Mn in the range in excess of 30,000 daltons.
12. An oriented device as claimed in claim 11 , wherein the polymeric component has molecular weight Mn in the range in of 50,000 to 500,000 daltons.
13. An oriented device as claimed in any one of claims 1 to 12 wherein the polymeric component is selected with intrinsic viscosity
(IV), in the range 1 to 10.
14. An oriented device as claimed in any one of claims 1 to 13 wherein the polymeric component contains fillers.
15. An oriented device according to claim 14, wherein the filler is an osteoconductive material.
16. An oriented device as claimed in any one of the previous claims provided in the form of fibres, drawn monoliths, spun polymer or moulded polymer.
17. An oriented device as claimed in any one of the previous claims used to produce high strength composites reinforced by component fibres, drawn monoliths, spun polymer or moulded polymer.
18. An oriented device as claimed in any one of the previous claims characterized by a tensile strength in range about 150 Mpa to about 2000 MPa for fibre form devices.
19. An oriented device as claimed in claim 18, characterized by a tensile strength in the range about 800 to about 2000 MPa.
20. An oriented device as claimed in claim 18 or 19, characterized by a tensile strength in the range about 800 to about 1000 MPa.
21. An oriented device as claimed in claim 18 or 19, characterized by a tensile strength in the range about 1000 to about 2000 MPa.
22. An oriented device as claimed in any of claims 1 to 17 characterized by a tensile strength in the range about 150 to about 800 MPa for drawn monoliths, spun polymer or moulded polymer.
23. A composite comprising an oriented device as hereinbefore defined in any of claims 1 to 22 provided within a biodegradable polymer matrix.
24. A composite as claimed in Claim 23 wherein a polymer matrix is selected from a polyester, more preferably PLA or the like and its isomers and (block) copolymers and blends thereof as hereinbefore defined in Claim 9 to 13.
25. A composite as claimed in claim 23 or 24 wherein the matrix component is formed from a homogeneous polymer blend comprising the matrix polymer in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which is a degradation accelerant or a precursor thereof, as defined in any of claims 2 to 8.
26. A composite as claimed in any of claims 23 to 25 which contains fillers such as osteoconductive materials and/or biological actives such as hydroxyapatite in the matrix and/or the oriented device.
27. A composite as claimed in any of claims 23 to 26 in the form of a suture anchor, soft tissue anchor, interference screw, tissue engineering scaffold, maxillo-facial plate, fracture fixation plate or rod.
28. A composite as claimed in any of claims 23 to 27characterised by a tensile strength in excess of about 150 MPa up to about 800 MPa.
29. A composite as claimed in claim 287, characterised by a tensile strength in the range about 250 to about 550 MPa.
30. A process for the preparation of an oriented implantable, biodegradable device comprising the steps of ;
i) preparing a polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant or a precursor thereof; and
ii) processing to orient polymer whereby polymer is in uniaxial, biaxial or triaxial orientation.
31. A process for the preparation of an oriented device as defined in any of claims 1 to 15 comprising preparing a polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant or a precursor thereof, as defined in any of claims 1 to 8, and processing to orient polymer whereby polymer is in uniaxial, biaxial or triaxial orientation.
32. A process as claimed in claim 30 or 31 wherein the polymer is cast, compression moulded or extruded into a form suitable for shaping and orienting or into the desired shape for orienting, and oriented by aligning melt phase polymer and cooling, more preferably by drawing, spinning or moulding to orient polymer chains in the direction of draw or spin, or axis or direction of moulding, and cooling.
33. A process for preparing a composite as claimed in any of Claims 22 to 28 comprising providing oriented device as defined in any of Claims 1 to 15 and combining with matrix polymer as hereinbefore defined in Claim 24 to 26.
34. The use of an oriented device or a composite thereof as hereinbefore defined in any of Claims 1 to 29 as an implantable biodegradable device such as a high strength trauma fixation device suitable for implantation into the human or animal body.
35. The use of claim 34, wherein the high strength trauma fixation device is selected from the group consisting of plates, screws, pins, rods, anchors or scaffolds.
36. The use according to claim 35, wherein the high strength trauma fixation device is selected from the group consisting of suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods.
PCT/GB2006/003049 2005-08-18 2006-08-16 High strength devices and composites WO2007020432A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008526546A JP2009504929A (en) 2005-08-18 2006-08-16 High-strength devices and composite materials
CA002619571A CA2619571A1 (en) 2005-08-18 2006-08-16 High strength devices and composites
EP06765297A EP1922091A2 (en) 2005-08-18 2006-08-16 High strength devices and composites
AU2006281248A AU2006281248A1 (en) 2005-08-18 2006-08-16 High strength devices and composites
US12/064,156 US20080305144A1 (en) 2005-08-18 2006-08-16 High Strength Devices and Composites

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516943.8 2005-08-18
GB0516943A GB0516943D0 (en) 2005-08-18 2005-08-18 High strength fibres and composites
GB0523318A GB0523318D0 (en) 2005-11-16 2005-11-16 High strength fibres and composites
GB0523318.4 2005-11-16

Publications (2)

Publication Number Publication Date
WO2007020432A2 true WO2007020432A2 (en) 2007-02-22
WO2007020432A3 WO2007020432A3 (en) 2007-12-21

Family

ID=37671232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003049 WO2007020432A2 (en) 2005-08-18 2006-08-16 High strength devices and composites

Country Status (6)

Country Link
US (1) US20080305144A1 (en)
EP (1) EP1922091A2 (en)
JP (1) JP2009504929A (en)
AU (1) AU2006281248A1 (en)
CA (1) CA2619571A1 (en)
WO (1) WO2007020432A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007313009A (en) * 2006-05-25 2007-12-06 Terumo Corp Stent
WO2009019477A2 (en) * 2007-08-07 2009-02-12 Smith & Nephew Plc Coating
WO2010017153A3 (en) * 2008-08-06 2011-03-31 Medtronic, Inc. Medical devices and methods including blends of biodegradable polymers
US9770534B2 (en) 2007-04-19 2017-09-26 Smith & Nephew, Inc. Graft fixation
US9815240B2 (en) 2007-04-18 2017-11-14 Smith & Nephew, Inc. Expansion moulding of shape memory polymers

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
CN101594831B (en) 2006-11-30 2011-09-14 史密夫和内修有限公司 Fiber reinforced composite material
JP5520814B2 (en) 2007-04-19 2014-06-11 スミス アンド ネフュー インコーポレーテッド Multimodal shape memory polymer
JP5286505B2 (en) * 2011-01-19 2013-09-11 東洋製罐株式会社 Biodegradable resin composition
WO2013038399A1 (en) * 2011-09-18 2013-03-21 Bio Plasmar Ltd Bio-degradable compositions and use thereof
US8834915B2 (en) 2012-03-30 2014-09-16 Manli International Ltd. Drug-containing bioabsorbable fibers and implants
US11325281B2 (en) * 2018-07-23 2022-05-10 Ut-Battelle, Llc Rapid manufacturing of tailored preforms
US11612754B2 (en) * 2018-12-21 2023-03-28 Tepha, Inc. Resorbable nonwoven pouches for medical device implants
CN111671981A (en) * 2020-06-24 2020-09-18 杭州锐健马斯汀医疗器材有限公司 Absorbable composite material for interface screw sheath and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635274A2 (en) * 1993-07-21 1995-01-25 United States Surgical Corporation Plasticizers for fibers used to form surgical devices
WO2000001426A1 (en) * 1998-07-07 2000-01-13 Smith & Nephew Plc Blend of bioresorbable polymers
WO2001046501A2 (en) * 1999-12-22 2001-06-28 Kimberly-Clark Worldwide, Inc. Synthetic fiber
WO2003004071A1 (en) * 2001-07-04 2003-01-16 Smith & Nephew Plc Biodegradable polymer systems
WO2003064531A1 (en) * 2002-01-31 2003-08-07 Smith & Nephew Plc High strength bioresorbables containing poly-glycolic acid
WO2005014718A1 (en) * 2003-07-19 2005-02-17 Smith & Nephew Plc High strength bioreabsorbable co-polymers

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758156R (en) * 1970-05-13 1971-04-28 Ethicon Inc ABSORBABLE SUTURE ELEMENT AND ITS
US3797499A (en) * 1970-05-13 1974-03-19 Ethicon Inc Polylactide fabric graphs for surgical implantation
US3736646A (en) * 1971-10-18 1973-06-05 American Cyanamid Co Method of attaching surgical needles to multifilament polyglycolic acid absorbable sutures
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
US4181983A (en) * 1977-08-29 1980-01-08 Kulkarni R K Assimilable hydrophilic prosthesis
US5110852A (en) * 1982-07-16 1992-05-05 Rijksuniversiteit Te Groningen Filament material polylactide mixtures
US4627952A (en) * 1982-09-03 1986-12-09 Celanese Corporation Injection molding process
US4523591A (en) * 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4636215A (en) * 1984-01-11 1987-01-13 Rei, Inc. Combination tray and condylar prosthesis for mandibular reconstruction and the like
US4990161A (en) * 1984-03-16 1991-02-05 Kampner Stanley L Implant with resorbable stem
US5527337A (en) * 1987-06-25 1996-06-18 Duke University Bioabsorbable stent and method of making the same
JP2561853B2 (en) * 1988-01-28 1996-12-11 株式会社ジェイ・エム・エス Shaped memory molded article and method of using the same
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
FR2641692A1 (en) * 1989-01-17 1990-07-20 Nippon Zeon Co Plug for closing an opening for a medical application, and device for the closure plug making use thereof
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
US5294395A (en) * 1989-09-01 1994-03-15 Ethicon, Inc. Thermal treatment of theraplastic filaments for the preparation of surgical sutures
DE58908155D1 (en) * 1989-09-15 1994-09-08 N Proizv Ob Edinenie Kompleksn ENDOPROTHESIS OF THE HIP JOINT.
US7208013B1 (en) * 1990-06-28 2007-04-24 Bonutti Ip, Llc Composite surgical devices
ATE131373T1 (en) * 1991-05-24 1995-12-15 Synthes Ag ABSORBABLE TENDON AND BONE REINFORCEMENT DEVICE
US5275601A (en) * 1991-09-03 1994-01-04 Synthes (U.S.A) Self-locking resorbable screws and plates for internal fixation of bone fractures and tendon-to-bone attachment
US5383931A (en) * 1992-01-03 1995-01-24 Synthes (U.S.A.) Resorbable implantable device for the reconstruction of the orbit of the human skull
US5333624A (en) * 1992-02-24 1994-08-02 United States Surgical Corporation Surgical attaching apparatus
US5407445A (en) * 1992-05-20 1995-04-18 Cytrx Corporation Gel composition for implant prosthesis and method of use
CA2124842C (en) * 1992-10-02 2003-07-15 Patrick R. Gruber A melt-stable lactide polymer fabric and process for manufacture thereof
US5437918A (en) * 1992-11-11 1995-08-01 Mitsui Toatsu Chemicals, Inc. Degradable non-woven fabric and preparation process thereof
US5716410A (en) * 1993-04-30 1998-02-10 Scimed Life Systems, Inc. Temporary stent and method of use
US5417712A (en) * 1994-02-17 1995-05-23 Mitek Surgical Products, Inc. Bone anchor
US5626861A (en) * 1994-04-01 1997-05-06 Massachusetts Institute Of Technology Polymeric-hydroxyapatite bone composite
US5634936A (en) * 1995-02-06 1997-06-03 Scimed Life Systems, Inc. Device for closing a septal defect
US5702656A (en) * 1995-06-07 1997-12-30 United States Surgical Corporation Process for making polymeric articles
FI98136C (en) * 1995-09-27 1997-04-25 Biocon Oy A tissue-soluble material and process for its manufacture
US5716413A (en) * 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
AU2759397A (en) * 1996-05-28 1998-01-05 1218122 Ontario Inc. Resorbable implant biomaterial made of condensed calcium phosphate particles
US5756651A (en) * 1996-07-17 1998-05-26 Chronopol, Inc. Impact modified polylactide
BR9711214A (en) * 1996-08-23 2000-01-11 Osteobiologics Inc Device and process for measuring a compression property of a material, and processes for determining cartilage health or disease and for making the device.
US5893850A (en) * 1996-11-12 1999-04-13 Cachia; Victor V. Bone fixation device
EP1018982B1 (en) * 1996-12-03 2005-03-09 Osteobiologics, Inc. Biodegradable polymeric film
US5733330A (en) * 1997-01-13 1998-03-31 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush-resistant locking stent
SE512050C2 (en) * 1997-01-21 2000-01-17 Nobel Biocare Ab Rotationally symmetrical leg anchoring element
US5977204A (en) * 1997-04-11 1999-11-02 Osteobiologics, Inc. Biodegradable implant material comprising bioactive ceramic
EP1014897B1 (en) * 1997-05-30 2008-10-29 Osteobiologics, Inc. Fiber-reinforced, porous, biodegradable implant device
GB9717433D0 (en) * 1997-08-19 1997-10-22 Univ Nottingham Biodegradable composites
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
US6248430B1 (en) * 1998-08-11 2001-06-19 Dainippon Ink And Chemicals, Inc. Lactic acid-based polymer laminated product and molded product
SE515572C2 (en) * 1998-09-09 2001-09-03 Lanka Ltd Implants, ways of making it and using it
US6248108B1 (en) * 1998-09-30 2001-06-19 Bionx Implants Oy Bioabsorbable surgical screw and washer system
US6255408B1 (en) * 1998-11-06 2001-07-03 Poly-Med, Inc. Copolyesters with minimized hydrolytic instability and crystalline absorbable copolymers thereof
EP1148830A1 (en) * 1999-02-04 2001-10-31 Synthes Ag Chur Bone screw
US6296645B1 (en) * 1999-04-09 2001-10-02 Depuy Orthopaedics, Inc. Intramedullary nail with non-metal spacers
US7033603B2 (en) * 1999-08-06 2006-04-25 Board Of Regents The University Of Texas Drug releasing biodegradable fiber for delivery of therapeutics
US6425923B1 (en) * 2000-03-07 2002-07-30 Zimmer, Inc. Contourable polymer filled implant
WO2002009768A2 (en) * 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
AU8298201A (en) * 2000-08-17 2002-02-25 Tyco Healthcare Sutures and coatings made from therapeutic absorbable glass
ES2294026T3 (en) * 2000-09-06 2008-04-01 Ap Pharma, Inc. DEGRADABLE POLYACETAL POLYMERS.
US6605090B1 (en) * 2000-10-25 2003-08-12 Sdgi Holdings, Inc. Non-metallic implant devices and intra-operative methods for assembly and fixation
US6719935B2 (en) * 2001-01-05 2004-04-13 Howmedica Osteonics Corp. Process for forming bioabsorbable implants
US6749639B2 (en) * 2001-08-27 2004-06-15 Mayo Foundation For Medical Education And Research Coated prosthetic implant
US6841111B2 (en) * 2001-08-31 2005-01-11 Basf Corporation Method for making a polyurea-polyurethane composite structure substantially free of volatile organic compounds
US6916321B2 (en) * 2001-09-28 2005-07-12 Ethicon, Inc. Self-tapping resorbable two-piece bone screw
US20030125745A1 (en) * 2001-11-05 2003-07-03 Bio One Tech Inc. Bone-fixing device
BR0214610A (en) * 2001-11-30 2004-09-14 Pfizer Controlled release polymeric compositions of bone growth promoting compounds
WO2003059203A1 (en) * 2001-12-21 2003-07-24 Smith & Nephew, Inc. Hinged joint system
WO2003080119A1 (en) * 2002-03-26 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Responsive biomedical composites
US20040024471A1 (en) * 2002-06-27 2004-02-05 Ferree Bret A. Bone cell covered arthroplasty devices
WO2004022000A2 (en) * 2002-09-05 2004-03-18 Ambrose Catherine G Antibiotic microspheres for treatment of infections and osteomyelitis
US7291345B2 (en) * 2002-12-12 2007-11-06 Osteotech, Inc. Formable and settable polymer bone composite and method of production thereof
EP1433489A1 (en) * 2002-12-23 2004-06-30 Degradable Solutions AG Biodegradable porous bone implant with a barrier membrane sealed thereto
EP1592728A2 (en) * 2003-01-16 2005-11-09 Carnegie-Mellon University Biodegradable polyurethanes and use thereof
US20070043376A1 (en) * 2003-02-21 2007-02-22 Osteobiologics, Inc. Bone and cartilage implant delivery device
WO2004082524A2 (en) * 2003-03-13 2004-09-30 William Marsh Rice University Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material
US7012106B2 (en) * 2003-03-28 2006-03-14 Ethicon, Inc. Reinforced implantable medical devices
EP1631206B1 (en) * 2003-06-12 2007-10-10 Synthes GmbH Surgical nail
FI120333B (en) * 2003-08-20 2009-09-30 Bioretec Oy A porous medical device and a method of making it
US7648504B2 (en) * 2003-09-09 2010-01-19 Bioretec Ltd Bioabsorbable band system
JP4251061B2 (en) * 2003-10-03 2009-04-08 ブリヂストンスポーツ株式会社 Golf club head
US7699879B2 (en) * 2003-10-21 2010-04-20 Warsaw Orthopedic, Inc. Apparatus and method for providing dynamizable translations to orthopedic implants
WO2005069884A2 (en) * 2004-01-16 2005-08-04 Osteobiologics, Inc. Bone-tendon-bone implant
US7378144B2 (en) * 2004-02-17 2008-05-27 Kensey Nash Corporation Oriented polymer implantable device and process for making same
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
US20060067971A1 (en) * 2004-09-27 2006-03-30 Story Brooks J Bone void filler
EP1883398A4 (en) * 2005-02-01 2012-06-06 Osteobiologics Inc Method and device for selective addition of a bioactive agent to a multi-phase implant
WO2007067625A2 (en) * 2005-12-06 2007-06-14 Tyco Healthcare Group Lp Bioabsorbable surgical composition
WO2007066339A1 (en) * 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Drug-delivering composite structures
BRPI0620047A2 (en) * 2005-12-21 2011-11-01 Synthes Gmbh bone plate set
KR101102475B1 (en) * 2006-06-28 2012-01-05 군제 가부시키가이샤 Bio-degradable/absorbable polymer having reduced metal catalyst content, and process for production thereof
US20080015578A1 (en) * 2006-07-12 2008-01-17 Dave Erickson Orthopedic implants comprising bioabsorbable metal
US8828419B2 (en) * 2006-10-06 2014-09-09 Cordis Corporation Bioabsorbable device having encapsulated additives for accelerating degradation
US8394488B2 (en) * 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
US8480718B2 (en) * 2006-12-21 2013-07-09 Warsaw Orthopedic, Inc. Curable orthopedic implant devices configured to be hardened after placement in vivo
US7771476B2 (en) * 2006-12-21 2010-08-10 Warsaw Orthopedic Inc. Curable orthopedic implant devices configured to harden after placement in vivo by application of a cure-initiating energy before insertion
WO2009043099A1 (en) * 2007-10-03 2009-04-09 Polynovo Biomaterials Limited High modulus polyurethane and polyurethane/urea compositions
US8323322B2 (en) * 2007-10-05 2012-12-04 Zimmer Spine, Inc. Medical implant formed from porous metal and method
FI124190B (en) * 2007-12-05 2014-04-30 Bioretec Oy Medical agent and preparation thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635274A2 (en) * 1993-07-21 1995-01-25 United States Surgical Corporation Plasticizers for fibers used to form surgical devices
WO2000001426A1 (en) * 1998-07-07 2000-01-13 Smith & Nephew Plc Blend of bioresorbable polymers
WO2001046501A2 (en) * 1999-12-22 2001-06-28 Kimberly-Clark Worldwide, Inc. Synthetic fiber
WO2003004071A1 (en) * 2001-07-04 2003-01-16 Smith & Nephew Plc Biodegradable polymer systems
WO2003064531A1 (en) * 2002-01-31 2003-08-07 Smith & Nephew Plc High strength bioresorbables containing poly-glycolic acid
WO2005014718A1 (en) * 2003-07-19 2005-02-17 Smith & Nephew Plc High strength bioreabsorbable co-polymers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUPTA ET AL: "Poly(lactic acid) fiber: An overview" PROGRESS IN POLYMER SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 32, no. 4, 23 March 2007 (2007-03-23), pages 455-482, XP005935217 ISSN: 0079-6700 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007313009A (en) * 2006-05-25 2007-12-06 Terumo Corp Stent
US9815240B2 (en) 2007-04-18 2017-11-14 Smith & Nephew, Inc. Expansion moulding of shape memory polymers
US9770534B2 (en) 2007-04-19 2017-09-26 Smith & Nephew, Inc. Graft fixation
JP2015013182A (en) * 2007-08-07 2015-01-22 スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company Coating
AU2008285487B2 (en) * 2007-08-07 2014-09-25 Smith & Nephew Plc Coating
JP2010535563A (en) * 2007-08-07 2010-11-25 スミス アンド ネフュー ピーエルシー Coating
AU2014277686B2 (en) * 2007-08-07 2016-05-05 Smith & Nephew Plc Coating
JP2017042634A (en) * 2007-08-07 2017-03-02 スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company Coating
WO2009019477A3 (en) * 2007-08-07 2010-01-21 Smith & Nephew Plc Coating
WO2009019477A2 (en) * 2007-08-07 2009-02-12 Smith & Nephew Plc Coating
WO2010017153A3 (en) * 2008-08-06 2011-03-31 Medtronic, Inc. Medical devices and methods including blends of biodegradable polymers
CN102143766A (en) * 2008-08-06 2011-08-03 麦德托尼克公司 Medical devices and methods including blends of biodegradable polymers
JP2011530331A (en) * 2008-08-06 2011-12-22 メドトロニック,インコーポレイテッド Medical devices and methods comprising blends of biodegradable polymers
US8129477B1 (en) 2008-08-06 2012-03-06 Medtronic, Inc. Medical devices and methods including blends of biodegradable polymers

Also Published As

Publication number Publication date
US20080305144A1 (en) 2008-12-11
WO2007020432A3 (en) 2007-12-21
JP2009504929A (en) 2009-02-05
EP1922091A2 (en) 2008-05-21
CA2619571A1 (en) 2007-02-22
AU2006281248A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
US20080305144A1 (en) High Strength Devices and Composites
US20090274742A1 (en) Multimodal high strength devices and composites
JP6995852B2 (en) Absorbent polymer blend composition with improved nucleation rate
US9173978B2 (en) Bioabsorbable polymeric compositions, processing methods, and medical devices therefrom
CA2452358C (en) Biodegradable polymer systems
EP3293228B1 (en) Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US9737629B2 (en) Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom
AU2014355033B2 (en) Absorbable polymeric blend compositions with precisely controllable absorption rates, processing methods, and dimensionally stable medical devices therefrom
WO2016025329A1 (en) Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
Bai et al. In vitro hydrolytic degradation of poly (para-dioxanone)/poly (D, L-lactide) blends
WO2009132021A1 (en) Absorbable copolyesters of poly(ethoxyethylene diglycolate) and glycolide
CN1826380A (en) High strength bioreabsorbable co-polymers
US20180325943A1 (en) Biocompatible Articles With Embedded Copper Ions and Copper Ion Releasing Coating
WO2007110611A1 (en) Composite material
JP2021529597A (en) Easy-absorbing copolymer composition for high-strength sutures with improved post-embedding strength retention
EP3720514B1 (en) Vacuum membrane thermoformed poly-4-hydroxybutyrate medical implants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006281248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008526546

Country of ref document: JP

Ref document number: 2006765297

Country of ref document: EP

Ref document number: 2619571

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006281248

Country of ref document: AU

Date of ref document: 20060816

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006281248

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006765297

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12064156

Country of ref document: US